Targeting obesity: From bench to bedside
Our team aims at discovering new pathophysiological targets, biomarkers and predictors of obesity and related comorbidity stages. To reach these aims, we develop large-scale approaches using innovative bioinformatics and complex systems’ modeling tools. Investigations are carried out in well-phenotyped obese subjects with various metabolic disorders and disease stages in whom data and biobanks are constituted. This strategy generates hypotheses on putative new cellular and molecular pathophysiological actors, which are then tested in in vitro and ex vivo models and in rodents models (genetically or diet-induced obese mice; models of bariatric surgery, knockouts).
Our main unifying working hypothesis is that inflammatory/immune unbalance in obesity, potentially influenced by modified (micro) environmental factors is central in adipose cell injury processes. This has major consequences on the systemic homeostasis associated with the biological deterioration of tissues located in WAT vicinity or at distant sites. Our purpose will be to identify relevant new targets and biomarkers associated with obesity comorbidities and resistance to weight loss. We believe that anomalies of some of these targets might also be shared among cardiometabolic diseases. Nutriomic will be developing specific programs to depict at cellular and molecular levels the cross talk between immune system and adipose cell phenotypes. The relationships between these perturbations and obesity comorbidities will be explored. Nutriomic will also investigate the importance of environment changes including nutritional switches on human metabolism and inflammation.